Overall U.S. approval rate for cancer drugs is only 8%, according to Tufts studyby Patricia Mayville-Cox, The Cancer Blog on Sep 09, 2007Filed under: Research  According to a study by the Tufts Center for the Study of Drug Development, only eight percent of cancer drugs that entered clinical development and testing in humans made it through to final approval. In comparison, during the same time period, 1993-1997, the U.S. has an approval rate of 20% for all new drugs. The number of overall cancer drug candidates that entered clinical trials increased during the same time period. Also, cancer drugs took an average of seven years to get through the clinical development and approval process compared with six years for all new drugs during the same time period. Read | Permalink | Email this | Linking Blogs | Comments
Be the first to comment on this article.
Add a commentPlease do not include any advertisements or offensive material. cancel |
